PROJECTS

Logo.JPG

The MDR project (HIV multidrug resistance pathways in the EuResist Integrated DataBase) aims at estimating the prevalence and trend over time of MDR (multidrug resistance) in HIV patients, using descriptive statistics, retaining high value because of the large sample size and wide representativeness of the EIDB.

 

In addition, the project aims at identifying factors associated with development of MDR and deriving successful treatment strategies in MDR patients, based on GSS of possible rescue therapies: these challenging and ambitious tasks will benefit from machine learning approaches and the use of probabilistic models, under the responsibility of a multidisciplinary team with excellent specific and cross-talk capability, well-established through decennial cooperation within the EuResist consortium. 

The MDR project started at March 2019. The study group includes clinicians, virologists and modelers with specific strong expertise in HIV drug resistance: Dr. A. Sönnerborg (KI), Dr. M. Zazzi (UNISI), Dr. R. Kaiser (UNIKOELN), : Dr. A.M. Vandamme (Rega Institute)

NEW!

The Poster "Declining incidence of HIV multidrug resistance in Europe" has won the Best Poster Award at the 18th European AIDS Conference held Online & London,
United Kingdom on October 27–30, 2021.

ViiV.png

Project supported by a grant from ViiV Healthcare S.r.l.

The Poster "Declining incidence of HIV multidrug resistance in Europe" has won the Best Poster Award at the 18th European AIDS Conference held Online & London, United Kingdom on October 27–30, 2021.

MDRaward.jpg

Publications

4-Class Resistance is rare in treatment experienced patients across Europe

M. Zazzi, A.M. Vandamme, B. Rossetti, M. Fabbiani, F. Incardona, K. Theys, A. Abecasis, C. Devaux, R. Kaiser, A. Sönnerborg, G. Pasculli, J. Vercauteren for the EuResist Network study group

CROI 2020

Saladini et al. paper immagine.jpg
CROI_2020-Poster-EuResist_V08_uploaded.j